This segment focuses on the research, development, and commercialization of novel therapies for various cancers. Key activities include the development of ONC201, ONC206, and ONC212, which are imipridone-based compounds targeting specific mutations and pathways in tumors. Research and development efforts involve preclinical studies, clinical trials, and regulatory submissions. The segment utilizes advanced methodologies in drug discovery, including targeted therapies and precision medicine approaches. The primary therapeutic areas include recurrent diffuse midline glioma, solid tumors, and hematological malignancies. The patient impact is significant, as these therapies aim to address unmet medical needs in cancer treatment. Market positioning is based on innovative drug candidates and strategic partnerships. Future opportunities include expanding the pipeline and securing regulatory approvals. Clinical trials and regulatory compliance are crucial aspects of this segment. Partnerships with research institutions and pharmaceutical companies are essential for advancing the development and commercialization of these therapies.

This segment is dedicated to the development and commercialization of antiviral drugs, with a primary focus on addressing unmet medical needs in infectious diseases. The lead product, TEMBEXA (brincidofovir), is a lipid conjugate developed as a medical countermeasure for smallpox. Research and development activities include clinical trials, regulatory submissions, and manufacturing processes. The segment utilizes advanced technologies in drug discovery and formulation. The therapeutic area is primarily focused on infectious diseases, with a specific emphasis on smallpox. The patient impact is significant, as these therapies aim to provide effective treatments for life-threatening viral infections. Market positioning is based on the development of innovative antiviral drugs and strategic partnerships. Future opportunities include expanding the product portfolio and securing regulatory approvals. Regulatory compliance and clinical validation are crucial aspects of this segment. Partnerships with government agencies and pharmaceutical companies are essential for advancing the development and commercialization of these therapies.